Drug Trial Radar · NCT02065791
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,401
Actual
Start
Feb 17, 2014
Primary completion
Oct 30, 2018
Study completion Oct 30, 2018
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- The George Institute for Global Health, Australia
- First posted
- Feb 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).
Conditions
- Diabetes Mellitus, Type 2
- Diabetic Nephropathy
Interventions
CanagliflozinDrug
One 100 mg over-encapsulated tablet orally once daily
PlaceboDrug
One matching placebo capsule orally (by mouth) once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) DeathTime frame: Up to 4.6 years
Locations
575 sites in 34 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Montgomery, Alabama
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Sherwood, Arkansas
Site not named
Bakersfield, California
Site not named
Chula Vista, California
Site not named
Covina, California
Site not named
Downey, California
Site not named
Fountain Valley, California
Site not named
Hawthorne, California
Site not named
Inglewood, California
Site not named
Laguna Hills, California
Site not named
Lakewood, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Lynwood, California
Site not named
Northridge, California
Site not named
Oakland, California
Site not named
Orange, California
Site not named
Pasadena, California
Site not named
Roseville, California
Site not named
Sacramento, California
Site not named
Salinas, California
Site not named
San Diego, California
Site not named
San Dimas, California
Site not named
Stanford, California
Site not named
Tustin, California
Site not named
Whittier, California
Site not named
Denver, Colorado
Site not named
Golden, Colorado
Site not named
Lakewood, Colorado
Site not named
Washington, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Coral Springs, Florida
Site not named
Doral, Florida
Site not named
Hialeah, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Showing 40 of 575 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.